Camp4 Therapeutics Poration Stock Fundamentals
| CAMP Stock | USD 5.55 0.09 1.65% |
CAMP4 THERAPEUTICS PORATION fundamentals help investors to digest information that contributes to CAMP4 THERAPEUTICS's financial success or failures. It also enables traders to predict the movement of CAMP4 Stock. The fundamental analysis module provides a way to measure CAMP4 THERAPEUTICS's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CAMP4 THERAPEUTICS stock.
At this time, CAMP4 THERAPEUTICS's Cost Of Revenue is relatively stable compared to the past year. As of 03/15/2025, Total Operating Expenses is likely to grow to about 93.1 M, while EBIT is likely to drop (20.3 M). CAMP4 | Select Account or Indicator |
CAMP4 THERAPEUTICS PORATION Company Shares Owned By Institutions Analysis
CAMP4 THERAPEUTICS's Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current CAMP4 THERAPEUTICS Shares Owned By Institutions | 56.95 % |
Most of CAMP4 THERAPEUTICS's fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CAMP4 THERAPEUTICS PORATION is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 56% of CAMP4 THERAPEUTICS PORATION are shares owned by institutions. This is 24.79% higher than that of the Communications Equipment sector and 18.78% higher than that of the Information Technology industry. The shares owned by institutions for all United States stocks is 45.25% lower than that of the firm.
CAMP4 THERAPEUTICS Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining CAMP4 THERAPEUTICS's current stock value. Our valuation model uses many indicators to compare CAMP4 THERAPEUTICS value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CAMP4 THERAPEUTICS competition to find correlations between indicators driving CAMP4 THERAPEUTICS's intrinsic value. More Info.CAMP4 THERAPEUTICS PORATION is rated below average in current valuation category among its peers. It is rated below average in shares outstanding category among its peers creating about 0.18 of Shares Outstanding per Current Valuation. The ratio of Current Valuation to Shares Outstanding for CAMP4 THERAPEUTICS PORATION is roughly 5.44 . As of 03/15/2025, Common Stock Shares Outstanding is likely to drop to about 39.3 M. Comparative valuation analysis is a catch-all technique that is used if you cannot value CAMP4 THERAPEUTICS by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.CAMP4 Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CAMP4 THERAPEUTICS's direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CAMP4 THERAPEUTICS could also be used in its relative valuation, which is a method of valuing CAMP4 THERAPEUTICS by comparing valuation metrics of similar companies.CAMP4 THERAPEUTICS is currently under evaluation in shares owned by institutions category among its peers.
CAMP4 THERAPEUTICS ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, CAMP4 THERAPEUTICS's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to CAMP4 THERAPEUTICS's managers, analysts, and investors.Environmental | Governance | Social |
CAMP4 Fundamentals
| Current Valuation | 109.74 M | ||||
| Shares Outstanding | 20.16 M | ||||
| Shares Owned By Insiders | 35.40 % | ||||
| Shares Owned By Institutions | 56.95 % | ||||
| Number Of Shares Shorted | 359.72 K | ||||
| Price To Earning | 318.57 X | ||||
| Revenue | 186.23 M | ||||
| Gross Profit | (37.93 M) | ||||
| EBITDA | (8.72 M) | ||||
| Net Income | (49.29 M) | ||||
| Cash And Equivalents | 47.72 M | ||||
| Cash Per Share | 1.29 X | ||||
| Total Debt | 178.68 M | ||||
| Current Ratio | 1.86 X | ||||
| Book Value Per Share | (158.04) X | ||||
| Cash Flow From Operations | (44.16 M) | ||||
| Short Ratio | 3.48 X | ||||
| Earnings Per Share | (2.64) X | ||||
| Price To Earnings To Growth | 0.08 X | ||||
| Target Price | 19.91 | ||||
| Number Of Employees | 53 | ||||
| Beta | 1.89 | ||||
| Market Capitalization | 102.82 M | ||||
| Total Asset | 54.95 M | ||||
| Retained Earnings | (159.96 M) | ||||
| Working Capital | 32.21 M | ||||
| Current Asset | 298.77 M | ||||
| Current Liabilities | 49.56 M | ||||
| Net Asset | 54.95 M |
About CAMP4 THERAPEUTICS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CAMP4 THERAPEUTICS PORATION's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CAMP4 THERAPEUTICS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CAMP4 THERAPEUTICS PORATION based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 22.9 M | 23.9 M | |
| Total Revenue | 167.6 M | 217.1 M | |
| Cost Of Revenue | 107.3 M | 133.1 M | |
| Sales General And Administrative To Revenue | 0.15 | 0.10 | |
| Research And Ddevelopement To Revenue | 0.07 | 0.06 | |
| Revenue Per Share | 4.53 | 4.73 | |
| Stock Based Compensation To Revenue | 0.03 | 0.02 | |
| Capex To Revenue | 0.07 | 0.04 | |
| Ebit Per Revenue | (0.05) | (0.05) |
Additional Tools for CAMP4 Stock Analysis
When running CAMP4 THERAPEUTICS's price analysis, check to measure CAMP4 THERAPEUTICS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CAMP4 THERAPEUTICS is operating at the current time. Most of CAMP4 THERAPEUTICS's value examination focuses on studying past and present price action to predict the probability of CAMP4 THERAPEUTICS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CAMP4 THERAPEUTICS's price. Additionally, you may evaluate how the addition of CAMP4 THERAPEUTICS to your portfolios can decrease your overall portfolio volatility.